Olli Pentikäinen
PhD
olli.pentikainen@utu.fi +358 40 521 6913 Kiinamyllynkatu 10 Turku ORCID identifier: https://orcid.org/0000-0001-7188-4016 |
Areas of expertise
Computer-Dependent Drug Discovery; Molecular Modeling; Protein structure-function relationship; Protein-protein interaction
Computer-Dependent Drug Discovery; Molecular Modeling; Protein structure-function relationship; Protein-protein interaction
Biography
Education:
MSc in (organic) chemistry 1995 (University of Joensuu, Finland)
PhD in Biochemistry 2003 (Åbo Akademi University)
Adjunct Professor in Biochemistry 2005- (University of Turku)
Positions:
2017- Professor of Medicinal Chemistry (University of Turku) 8/2017
2011- Senior Lecturer in Cell and Molecular Biology (University of Jyväskylä)
2015 Visiting Senior Scientist (University of Innsbruck, Austria)
2005-2006 Visiting Senior Scientist (University of Bristol, UK)
1999-2005 Manager in Molecular Discovery (FBD Ltd)
Education:
MSc in (organic) chemistry 1995 (University of Joensuu, Finland)
PhD in Biochemistry 2003 (Åbo Akademi University)
Adjunct Professor in Biochemistry 2005- (University of Turku)
Positions:
2017- Professor of Medicinal Chemistry (University of Turku) 8/2017
2011- Senior Lecturer in Cell and Molecular Biology (University of Jyväskylä)
2015 Visiting Senior Scientist (University of Innsbruck, Austria)
2005-2006 Visiting Senior Scientist (University of Bristol, UK)
1999-2005 Manager in Molecular Discovery (FBD Ltd)
Research
Our research focuses on discovery of efficient drug candidates and development of novel methods for that purpose. Especially our research on cancer drug targets that have been considered highly difficult, together with risk analysis of drug candidates, pave the road for safer drugs.
Our research focuses on discovery of efficient drug candidates and development of novel methods for that purpose. Especially our research on cancer drug targets that have been considered highly difficult, together with risk analysis of drug candidates, pave the road for safer drugs.
Publications
- Inhibition of human CYP1 enzymes by a classical inhibitor α-naphthoflavone and a novel inhibitor N-(3, 5-dichlorophenyl)cyclopropanecarboxamide: An in vitro and in silico study (2020)
- Chemical Biology and Drug Design
(A1 Refereed original research article in a scientific journal) - Inhibition of Pneumolysin Cytotoxicity by Hydrolysable Tannins (2020)
- Antibiotics
(A1 Refereed original research article in a scientific journal) - In vitro glucuronidation of 7-hydroxycoumarin derivatives in intestine and liver microsomes of Beagle dogs (2020)
- European Journal of Pharmaceutical Sciences
(A1 Refereed original research article in a scientific journal) - In vitro sulfonation of 7-hydroxycoumarin derivatives in liver cytosol of human and six animal species (2020)
- Xenobiotica
(A1 Refereed original research article in a scientific journal) - Screening of Natural Products Targeting SARS-CoV-2-ACE2 Receptor Interface - A MixMD Based HTVS Pipeline (2020)
- Frontiers in Chemistry
(A1 Refereed original research article in a scientific journal) - A Practical Perspective: The Effect of Ligand Conformers on the Negative Image-Based Screening (2019)
- International Journal of Molecular Sciences
(A1 Refereed original research article in a scientific journal) - Development of new Coumarin-based profluorescent substrates for human cytochrome P450 enzymes (2019)
- Xenobiotica
(A1 Refereed original research article in a scientific journal) - Fragment- and negative image-based screening of phosphodiesterase 10A inhibitors (2019)
- Chemical Biology and Drug Design
(A1 Refereed original research article in a scientific journal) - Getting Docking into Shape Using Negative Image-Based Restoring (2019)
- Journal of Chemical Information and Modeling
(A1 Refereed original research article in a scientific journal) - Suitability of MMGBSA for the selection of correct ligand binding modes from docking results (2019)
- Chemical Biology and Drug Design
(A1 Refereed original research article in a scientific journal)



